SynthesisMedicine2021
Comorbidities' potential impacts on severe and non-severe patients with COVID-19: A systematic review and meta-analysis.
Synthesis in Medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 69 citations in OpenAlex.
- Relationship between acute coronary syndrome and coronavirus disease 2019 infection and vaccination type: a retrospective observational study.BMC infectious diseases · 2026Observational
- Current Landscape of the Interrelationship Between Periodontitis, Type 2 Diabetes Mellitus, and COVID-19.International journal of molecular sciences · 2025Review
- Membrane Protein of SARS-CoV-2 Promotes the Production of CXCL10 and Apoptosis of Myocardial Cells.Cardiovascular toxicology · 2025Article
- Article
- Comorbidity patterns associated with severe COVID-19 outcomes: A cohort study based on the UK Biobank.PloS one · 2025Article
- The long-term effects of COVID-19 on oxygen carrying capacity in adults at the University of Limpopo, South Africa.Frontiers in medicine · 2025Article
- Prospective Variation of Cytokine Trends during COVID-19: A Progressive Approach from Disease Onset until Outcome.International journal of molecular sciences · 2024Article
- Chemerin Levels in COVID-19 Are More Affected by Underlying Diseases than by the Virus Infection Itself.Biomedicines · 2024Article
- Risk mapping of respiratory viral transmission and disease severity using individual and environmental health parameters: A scoping review and protocol analysis.One health (Amsterdam, Netherlands) · 2024Review
- Cholesterol and COVID-19-therapeutic opportunities at the host/virus interface during cell entry.Life science alliance · 2024Review
- Article
- Evaluation of Inflammatory Markers in Patients with COVID-19 Combined with Type 2 Diabetes Mellitus.Risk management and healthcare policy · 2024Article
- Proteomics validate circulating GDF-15 as an independent biomarker for COVID-19 severity.Frontiers in immunology · 2024Article
- Pre-existing neurological conditions and COVID-19 co-infection: Data from systematic reviews, meta-analyses, and scoping reviews.Journal of the neurological sciences · 2023Review
- A Comparison between SARS-CoV-2 and Gram-Negative Bacteria-Induced Hyperinflammation and Sepsis.International journal of molecular sciences · 2023Review
- Impact of COVID-19 on Cardiovascular Disease.Viruses · 2023Review
- Individual and mutual effects of diabetes, hypertension, and obesity on acute respiratory distress syndrome mortality rates in clinical patients: a multicentre study.Frontiers in public health · 2023Article
- Exploring Hematological Parameters and Their Prognostic Value in Adult COVID-19 Patients: Insights from Mogadishu, Somalia.Advances in hematology · 2023Article
- Patients with type 1 and type 2 diabetes hospitalized with COVID-19 in comparison with influenza: mortality and cardiorenal complications assessed by nationwide Swedish registry data.Cardiovascular diabetology · 2022Article
- Age and Comorbidities Predict COVID-19 Outcome, Regardless of Innate Immune Response Severity: A Single Institutional Cohort Study.Critical care explorations · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundAn ongoing outbreak of pneumonia associated with the severe acute respiratory coronavirus (SARS-CoV-2) emerged in December 2019 in Wuhan, China. Epidemiologic evidence suggests that patients with comorbidities and novel coronavirus disease 2019 (COVID-19) infection may have poor survival outcomes. However, the risk of these coexisting medical conditions in severe and non-severe cases has not been systematically reported. PURPOSE: The present study aimed to estimate the association of chronic comorbidities in severe and non-severe cases.
methodsA literature search was conducted using the databases PubMed, Embase, China National Knowledge Infrastructure (CNKI), and Wanfang Database, Chinese Scientific Journals Full-text Database (CQVIP) from the inception dates to April 1, 2020, to identify cohort studies assessing comorbidity and risk of adverse outcome. Either a fixed- or random-effects model was used to calculate the overall combined risk estimates.
resultsA total of 22 studies involving 3286 patients with laboratory-confirmed COVID-19 were included in the analysis. Overall, compared with the patients with non-severe cases, the pooled odds ratios (ORs) of hypertension, diabetes mellitus, and cardiovascular, cerebrovascular, and respiratory diseases in patients with severe cases were 2.79 (95% confidence intervals [95% CI]: 1.66-4.69), 1.64 (95% CI: 2.30-1.08), 1.79 (95% CI: 1.08-2.96), 3.92 (95% CI: 2.45-6.28), and 1.98 (95% CI: 1.26-3.12), respectively.
conclusionsThis meta-analysis supports the finding that chronic comorbidities may contribute to severe outcome in patients with COVID-19. According to the findings of the present study, old age and 2 or more comorbidities are significantly impactful to COVID-19 outcomes in hospitalized patients in China.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.